GO:0008111 alpha-methylacyl-CoA racemase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008111 defines the molecular function that interconverts (2S)- and (2R)-2-methylacyl-CoA esters, a step required for peroxisomal and mitochondrial metabolism of branched-chain fatty acids and bile acid intermediates.
• The enzyme responsible, alpha-methylacyl-CoA racemase (AMACR, also called P504S), is encoded by AMACR and is a well-established prostate cancer biomarker.
• Loss-of-function mutations in AMACR cause alpha-methylacyl-CoA racemase deficiency, a rare peroxisomal disorder with variable neurological and hepatic phenotypes.
• AMACR is a validated drug target; small-molecule inhibitors and 2-arylthiopropanoyl-CoA analogues have been developed as potential anti-prostate cancer agents.
• Kinetic, structural, and NMR-based methods have provided detailed mechanistic insight into substrate recognition and catalysis by AMACR from both human and Mycobacterium tuberculosis.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of AMACR function in cancer, peroxisomal disease, and bile acid metabolism.
Description
Alpha-methylacyl-CoA racemase activity (GO:0008111) is a molecular function that catalyzes the reversible epimerization of (2S)-2-methylacyl-CoA to (2R)-2-methylacyl-CoA. This racemization step is essential because only the (2R)-isomer can undergo beta-oxidation for branched-chain fatty acids such as pristanic acid, while the (2S)-isomer is required for bile acid synthesis from intermediates like dihydroxycholestanoic acid and trihydroxycholestanoic acid. The enzyme responsible, alpha-methylacyl-CoA racemase (AMACR; P504S), is a peroxisomal and mitochondrial protein that has attracted intense research interest because of its dual role in lipid metabolism and its marked overexpression in prostate cancer and other malignancies. From a research perspective, GO:0008111 is important because it connects a single enzymatic activity to diverse physiological processes, including fatty acid oxidation, bile acid biosynthesis, and cellular detoxification of branched-chain substrates. Defects in this activity lead to alpha-methylacyl-CoA racemase deficiency, a rare peroxisomal disorder with heterogeneous clinical presentations ranging from adult-onset neuropathy to severe neonatal liver disease. In oncology, AMACR is one of the most sensitive immunohistochemical markers for prostate adenocarcinoma, and its enzymatic activity is being explored as a therapeutic target. This article provides a research-grade overview of GO:0008111, covering its definition, catalytic mechanism, key genes, regulation, disease associations, and the experimental models and methods used to study it. All statements are based on published literature and authoritative QuickGO data, with inline citations to verified PubMed references-.
alpha-methylacyl-CoA racemase activity At A Glance
| GO ID | GO:0008111 |
|---|---|
| GO term | alpha-methylacyl-CoA racemase activity |
| Ontology | molecular_function |
| Synonym | 2-methylacyl-CoA 2-epimerase activity |
| Definition | Catalysis of the reaction: (2S)-2-methylacyl-CoA = (2R)-2-methylacyl-CoA. |
| Major function | Interconversion of (2S)- and (2R)-2-methylacyl-CoA esters for branched-chain fatty acid oxidation and bile acid synthesis. |
| Representative enzyme | Alpha-methylacyl-CoA racemase (AMACR; P504S), encoded by AMACR. |
| Subcellular localization | Peroxisomes and mitochondria. |
| Associated diseases | Alpha-methylacyl-CoA racemase deficiency; prostate cancer and other malignancies. |
| Research relevance | Cancer biomarker, drug target, peroxisomal disorder, bile acid metabolism. |
What Is GO:0008111?
GO:0008111, alpha-methylacyl-CoA racemase activity, is defined by QuickGO as the catalysis of the reaction: (2S)-2-methylacyl-CoA = (2R)-2-methylacyl-CoA. In other words, it is the enzyme activity that interconverts the two stereoisomers of 2-methylacyl-CoA esters, a process also known as 2-methylacyl-CoA 2-epimerase activity. This racemization is essential for the complete beta-oxidation of branched-chain fatty acids and for the synthesis of bile acids, because different metabolic pathways require specific stereoisomers of 2-methylacyl-CoA intermediates.
Why Is alpha-methylacyl-CoA racemase activity Important in Cell Biology?
GO:0008111 is important because it enables the stereochemical conversion required for two fundamental metabolic pathways: peroxisomal beta-oxidation of branched-chain fatty acids and bile acid biosynthesis. Without this activity, intermediates such as pristanic acid and dihydroxycholestanoic acid accumulate, leading to cellular toxicity and clinical disease. In addition, AMACR overexpression is a hallmark of prostate cancer and several other cancers, making the enzyme both a diagnostic biomarker and a potential therapeutic target. Understanding the molecular function of GO:0008111 therefore has direct implications for rare metabolic disorders and for oncology.
• Required for beta-oxidation of branched-chain fatty acids such as pristanic acid and phytanic acid.
• Essential for bile acid synthesis from 2-methylacyl-CoA intermediates.
• Loss-of-function mutations cause alpha-methylacyl-CoA racemase deficiency, a rare peroxisomal disorder.
• AMACR is a highly sensitive immunohistochemical marker for prostate adenocarcinoma (P504S).
• Enzyme activity is a validated target for anti-prostate cancer drug discovery.
• Provides a model system for studying enzyme stereochemistry and substrate recognition.
• Links peroxisomal and mitochondrial metabolism through shared intermediates.
• Kinetic and structural studies inform inhibitor design and mechanistic enzymology.
• Clinical phenotypes of AMACR deficiency are variable, requiring genetic and biochemical diagnosis.
• CRISPR models enable causal testing of AMACR function in disease and metabolism.
Molecular Mechanism of alpha-methylacyl-CoA racemase activity
Substrate recognition and binding
In simple terms: The enzyme grabs a specific 2-methylacyl-CoA molecule and holds it in place for chemical conversion.
AMACR recognizes 2-methylacyl-CoA esters with high specificity, binding the acyl chain and the CoA moiety through a network of hydrogen bonds and hydrophobic interactions. Structural and kinetic studies of the Mycobacterium tuberculosis enzyme have revealed detailed active-site residues that determine acyl-CoA ester recognition and chain-length preference. The human enzyme similarly accommodates a range of 2-methylacyl-CoA substrates, including pristanoyl-CoA and dihydroxycholestanoyl-CoA.
Catalytic epimerization
In simple terms: The enzyme flips the stereochemistry of the substrate from S to R or R to S without adding or removing atoms.
The racemization reaction proceeds via abstraction of the alpha-proton from the 2-methylacyl-CoA substrate, forming an enolate intermediate, followed by reprotonation from the opposite face to yield the opposite stereoisomer. This mechanism is consistent with the observed equilibrium between (2S)- and (2R)-2-methylacyl-CoA and with kinetic isotope effect studies. The reaction is reversible and does not require cofactors such as NAD+ or FAD.
Role in branched-chain fatty acid oxidation
In simple terms: The enzyme prepares branched fats so they can be broken down for energy.
For branched-chain fatty acids such as pristanic acid, beta-oxidation requires the (2R)-isomer of 2-methylacyl-CoA. AMACR converts the (2S)-isomer, which is produced by initial oxidation steps, into the (2R)-isomer, allowing continued rounds of beta-oxidation. Deficiency of this activity leads to accumulation of pristanic acid and other branched-chain fatty acids, contributing to the clinical phenotype of AMACR deficiency.
Role in bile acid synthesis
In simple terms: The enzyme helps make bile acids from cholesterol breakdown products.
Bile acid synthesis from cholesterol requires the conversion of dihydroxycholestanoic acid (DHCA) and trihydroxycholestanoic acid (THCA) to their CoA esters and subsequent racemization by AMACR. The (2R)-isomers of these intermediates are substrates for peroxisomal beta-oxidation, which shortens the side chain to produce cholic acid and chenodeoxycholic acid. Impaired AMACR activity can therefore affect bile acid production and liver function.
Inhibition and pharmacological targeting
In simple terms: Drugs can block this enzyme, which may slow cancer growth.
Small-molecule inhibitors and 2-arylthiopropanoyl-CoA analogues have been developed to inhibit AMACR activity as potential anti-prostate cancer agents. Structure-activity relationship studies have identified key pharmacophores for potent inhibition, and these compounds are useful tools for probing the cellular consequences of reduced racemase activity. Such inhibitors may also have utility in studying peroxisomal metabolism.
Key Genes Involved in GO:0008111 alpha-methylacyl-CoA racemase activity
The following genes and proteins are directly or functionally associated with alpha-methylacyl-CoA racemase activity (GO:0008111) and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AMACR | Encodes alpha-methylacyl-CoA racemase, the enzyme catalyzing GO:0008111 | Biomarker for prostate cancer; target for inhibitor development; mutated in AMACR deficiency |
| ACOX1 | Peroxisomal acyl-CoA oxidase 1, first step of fatty acid beta-oxidation | Functional partner in branched-chain fatty acid oxidation |
| ACOX2 | Peroxisomal acyl-CoA oxidase 2, involved in bile acid intermediate oxidation | Linked to bile acid synthesis and peroxisomal beta-oxidation |
| HSD17B4 | D-bifunctional protein, peroxisomal beta-oxidation | Defects cause peroxisomal disorders with overlapping phenotypes |
| SCP2 | Sterol carrier protein 2, involved in lipid transfer and peroxisomal beta-oxidation | May influence substrate availability for AMACR |
| CYP7A1 | Cholesterol 7-alpha-hydroxylase, rate-limiting for bile acid synthesis | Upstream of AMACR-dependent bile acid pathways |
| CYP27A1 | Sterol 27-hydroxylase, alternative bile acid synthesis | Provides intermediates for AMACR-dependent racemization |
| BAAT | Bile acid-CoA:amino acid N-acyltransferase | Conjugates bile acids; related to bile acid metabolism |
| SLC27A2 | Fatty acid transport protein 2, activates branched-chain fatty acids to CoA esters | Generates substrates for AMACR |
| ACAA1 | Peroxisomal 3-ketoacyl-CoA thiolase | Downstream of AMACR in beta-oxidation |
| PEX5 | Peroxisomal targeting signal receptor | Required for peroxisomal import of AMACR |
| PEX7 | Peroxisomal targeting signal 2 receptor | Import of AMACR and other peroxisomal enzymes |
| HNF4A | Hepatocyte nuclear factor 4 alpha, transcription factor | Regulates bile acid and lipid metabolism genes |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates peroxisomal beta-oxidation genes |
| NR1H4 | Farnesoid X receptor, bile acid sensor | Feedback regulation of bile acid synthesis |
| MT-AMACR | Mycobacterium tuberculosis AMACR homolog | Model enzyme for mechanistic and structural studies |
| AMACR1A | Human AMACR isoform 1A | Target of inhibitors; studied in prostate cancer |
| AMACR1B | Human AMACR isoform 1B | Alternative isoform with distinct tissue expression |
How Is alpha-methylacyl-CoA racemase activity Regulated?
The expression and activity of AMACR are regulated at multiple levels. Transcription of AMACR is influenced by nuclear receptors and transcription factors involved in lipid and bile acid metabolism, including HNF4A, PPARA, and NR1H4, which coordinate peroxisomal beta-oxidation and bile acid synthesis. Post-transcriptionally, AMACR protein levels can be modulated by alternative splicing, producing isoforms with different tissue distributions and catalytic properties. In cancer, AMACR is markedly overexpressed through mechanisms that are not fully understood but may involve androgen signaling and other oncogenic pathways. Enzyme activity itself can be regulated by substrate availability, product inhibition, and the redox state of the peroxisomal environment. Pharmacological inhibition by small molecules provides an additional layer of regulation for experimental studies.
alpha-methylacyl-CoA racemase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AMACR | Alpha-methylacyl-CoA racemase deficiency; neuropathy; liver dysfunction | Amacr knockout mouse; patient-derived fibroblasts; CRISPR point-mutation cell lines |
| AMACR | Prostate cancer; biomarker and therapeutic target | Prostate cancer cell lines (LNCaP, PC-3) with AMACR knockout or overexpression; xenograft models |
| AMACR | Bile acid synthesis defects; cholestasis | Liver-specific Amacr knockout mice; hepatocyte cell models |
| ACOX1 | Peroxisomal acyl-CoA oxidase deficiency; overlapping peroxisomal disorder | Acox1 knockout mice; patient fibroblasts |
| HSD17B4 | D-bifunctional protein deficiency; peroxisomal disorder | Hsd17b4 knockout models; CRISPR knockout cell lines |
Alpha-methylacyl-CoA racemase deficiency
Biallelic loss-of-function mutations in AMACR cause alpha-methylacyl-CoA racemase deficiency, a rare peroxisomal disorder characterized by accumulation of pristanic acid and bile acid intermediates. Clinical presentations are highly variable and can include adult-onset sensory-motor neuropathy, seizures, cognitive decline, and liver dysfunction. Diagnosis relies on biochemical profiling of plasma fatty acids and genetic testing, and management is primarily supportive.
Prostate cancer and other malignancies
AMACR (P504S) is overexpressed in the vast majority of prostate adenocarcinomas and is widely used as an immunohistochemical marker to distinguish malignant from benign prostate tissue. The enzyme is also overexpressed in some other cancers, including colorectal and breast carcinomas. Because AMACR activity supports branched-chain fatty acid oxidation and may contribute to cancer cell metabolism, it is considered a potential therapeutic target, and inhibitors have been developed as anti-prostate cancer agents.
Bile acid metabolism and liver disease
AMACR is required for the peroxisomal steps of bile acid synthesis, and its deficiency can lead to abnormal bile acid profiles and cholestatic liver disease. In chronic liver disease, alterations in bile acid homeostasis can affect AMACR-dependent pathways, and bile acids themselves act as signaling molecules that regulate lipid and glucose metabolism. Understanding AMACR function in the liver is therefore relevant to cholestasis and other hepatobiliary disorders.
From alpha-methylacyl-CoA racemase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of AMACR affect branched-chain fatty acid oxidation? | AMACR knockout cell lines (HepG2, HEK293) and Amacr knockout mice |
| How do specific AMACR mutations alter enzyme activity? | Point-mutation knock-in cell lines expressing mutant AMACR |
| Can AMACR overexpression drive prostate cancer phenotypes? | Prostate cancer cell lines with doxycycline-inducible AMACR overexpression |
| What is the subcellular localization of AMACR? | Tagged knock-in (e.g., GFP-AMACR) in cell lines; confocal imaging |
| Do AMACR inhibitors reduce cancer cell growth? | 3D spheroid and xenograft models treated with small-molecule inhibitors |
| How does AMACR deficiency affect bile acid synthesis? | Liver-specific Amacr knockout mice and primary hepatocytes |
How to Study the alpha-methylacyl-CoA racemase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Coupled enzyme assay | AMACR catalytic activity and kinetics | Determining Km, Vmax, and inhibitor IC50 |
| NMR spectroscopy | Real-time interconversion of stereoisomers | Mechanistic studies of racemization |
| X-ray crystallography | Three-dimensional structure of AMACR | Active-site mapping and inhibitor design |
| LC-MS/MS metabolomics | Levels of pristanic acid, DHCA, THCA | Diagnosis of AMACR deficiency; metabolic profiling |
| Immunohistochemistry | AMACR protein expression in tissues | Prostate cancer diagnosis (P504S) |
| Western blot | AMACR protein levels | Validation of knockout or overexpression |
| Confocal microscopy | Subcellular localization of tagged AMACR | Peroxisomal targeting studies |
| CRISPR screening | Genes affecting AMACR dependency | Identifying synthetic lethal interactions |
Enzyme activity assays
AMACR activity can be measured using coupled enzyme assays, chiral chromatography, or NMR-based methods that monitor the interconversion of (2S)- and (2R)-2-methylacyl-CoA substrates. These assays are essential for determining kinetic parameters, substrate specificity, and inhibitor potency.
Structural biology
X-ray crystallography and molecular modeling of AMACR from human and Mycobacterium tuberculosis have revealed the active-site architecture and substrate-binding residues. These structural insights guide the design of selective inhibitors and help explain the effects of disease-causing mutations.
Metabolomics and lipidomics
Mass spectrometry-based metabolomics and lipidomics can quantify pristanic acid, DHCA, THCA, and other 2-methylacyl-CoA intermediates in cells and tissues. These methods are used to diagnose AMACR deficiency and to assess the metabolic consequences of AMACR knockout or inhibition.
Immunohistochemistry and imaging
Immunohistochemistry for AMACR (P504S) is a standard diagnostic tool in prostate pathology. Fluorescence microscopy of tagged AMACR allows assessment of subcellular localization and co-localization with peroxisomal markers.
How CRISPR Can Be Used to Study GO:0008111 alpha-methylacyl-CoA racemase activity
Knockout
CRISPR-Cas9 knockout of AMACR in cell lines such as HepG2, HEK293, or prostate cancer cells abolishes racemase activity and leads to accumulation of (2S)-2-methylacyl-CoA intermediates. These models are used to study the metabolic consequences of AMACR loss, including effects on branched-chain fatty acid oxidation and bile acid synthesis. Knockout models also help validate the specificity of AMACR inhibitors.
Point Mutation
Point mutations identified in patients with AMACR deficiency can be introduced into cell lines using CRISPR prime editing or homology-directed repair to assess their impact on enzyme activity, protein stability, and subcellular localization. Such models provide genotype-phenotype correlations and help distinguish pathogenic from benign variants.
Knock-in
Knock-in of epitope tags (e.g., FLAG, GFP) or fluorescent proteins at the endogenous AMACR locus enables real-time tracking of protein expression and localization without overexpression artifacts. Knock-in of disease-associated mutations also allows study of their effects under endogenous regulatory control.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of AMACR can model the enzyme's upregulation in prostate cancer and other malignancies. Overexpression models are used to test whether increased racemase activity promotes cancer cell proliferation, survival, or metabolic reprogramming. They also facilitate biochemical purification of the enzyme for structural and kinetic studies.
How EDITGENE Supports alpha-methylacyl-CoA racemase activity Research
Researchers studying alpha-methylacyl-CoA racemase activity-related genes often need to determine whether a candidate gene is causally involved in peroxisomal metabolism, bile acid synthesis, or cancer cell growth. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that enable such causal inferences.
Contact EDITGENE today to design your custom CRISPR model for alpha-methylacyl-CoA racemase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AMACR Knockout HEK293 Cell Line | EDJ-KQ51120 | Human | 23600 | Details Get a Quote |
| AMACR Knockout HeLa Cell Line | EDJ-KQ55779 | Human | 23600 | Details Get a Quote |
| AMACR Knockout A-549 Cell Line | EDJ-KQ64274 | Human | 23600 | Details Get a Quote |
| AMACR Knockout HCT 116 Cell Line | EDJ-KQ72720 | Human | 23600 | Details Get a Quote |
Frequently Asked Questions About alpha-methylacyl-CoA racemase activity
What is alpha-methylacyl-CoA racemase activity?
Alpha-methylacyl-CoA racemase activity (GO:0008111) is the enzyme activity that interconverts (2S)-2-methylacyl-CoA and (2R)-2-methylacyl-CoA, a step required for branched-chain fatty acid oxidation and bile acid synthesis.
What gene encodes alpha-methylacyl-CoA racemase?
The AMACR gene encodes alpha-methylacyl-CoA racemase, also known as P504S, a peroxisomal and mitochondrial enzyme.
What diseases are associated with AMACR deficiency?
AMACR deficiency causes a rare peroxisomal disorder with variable neurological and hepatic symptoms, including neuropathy, seizures, and liver dysfunction.
Why is AMACR a prostate cancer marker?
AMACR is overexpressed in the majority of prostate adenocarcinomas and is used as an immunohistochemical marker (P504S) to distinguish malignant from benign prostate tissue.
What is the reaction catalyzed by GO:0008111?
The reaction is (2S)-2-methylacyl-CoA = (2R)-2-methylacyl-CoA, a reversible epimerization.
How is AMACR activity measured?
AMACR activity is measured using coupled enzyme assays, chiral chromatography, or NMR-based methods that monitor stereoisomer interconversion.
What are the substrates of AMACR?
Substrates include pristanoyl-CoA, dihydroxycholestanoyl-CoA, and other 2-methylacyl-CoA esters derived from branched-chain fatty acids and bile acid intermediates.
Can AMACR be targeted for cancer therapy?
Yes, small-molecule inhibitors of AMACR have been developed and show potential as anti-prostate cancer agents in preclinical studies.
What model systems are used to study AMACR function?
Common models include AMACR knockout cell lines, point-mutation knock-ins, overexpression cell lines, and Amacr knockout mice.
Where is AMACR located in the cell?
AMACR is localized primarily in peroxisomes and also in mitochondria, where it participates in lipid metabolism.
Conclusion
Alpha-methylacyl-CoA racemase activity (GO:0008111) is a fundamental enzymatic function that enables the stereochemical conversion of 2-methylacyl-CoA esters, supporting branched-chain fatty acid oxidation and bile acid synthesis. Its clinical relevance spans rare peroxisomal disorders and common cancers, particularly prostate cancer, where AMACR serves as a diagnostic biomarker and potential therapeutic target. Continued research using CRISPR-engineered cell and animal models, combined with structural and metabolomic approaches, will further clarify the mechanistic roles of this activity in health and disease. EDITGENE provides the tools and expertise to generate precisely engineered models for studying AMACR and related metabolic genes, accelerating discoveries in peroxisomal biology and oncology.
References
- 1. Klouwer FCC et al.. 2024. Redefining the phenotype of alpha-methylacyl-CoA racemase (AMACR) deficiency.. Orphanet J Rare Dis 19(1):350 PMID: 39313810
- 2. Farooqui N et al.. 2022. A Current Understanding of Bile Acids in Chronic Liver Disease.. J Clin Exp Hepatol 12(1):155-173 PMID: 35068796
- 3. Mojanaga OO et al.. 2024. α-Methylacyl-CoA Racemase from Mycobacterium tuberculosis-Detailed Kinetic and Structural Characterization of the Active Site.. Biomolecules 14(3) PMID: 38540719
- 4. Mojanaga OO et al.. 2025. Molecular basis of acyl-CoA ester recognition by α-methylacyl-CoA racemase from Mycobacterium tuberculosis.. J Biol Chem 301(7):110302 PMID: 40447188
- 5. Yevglevskis M et al.. 2019. Novel 2-arylthiopropanoyl-CoA inhibitors of α-methylacyl-CoA racemase 1A (AMACR; P504S) as potential anti-prostate cancer agents.. Bioorg Chem 92:103263 PMID: 31536953
- 6. Woodman TJ et al.. 2023. Analysis of enzyme reactions using NMR techniques: A case study with α-methylacyl-CoA racemase (AMACR).. Methods Enzymol 690:159-209 PMID: 37858529
- 7. Selamioğlu A et al.. 2024. Variable clinical phenotypes of alpha-methylacyl-CoA racemase deficiency: Report of four cases and review of the literature.. JIMD Rep 65(5):305-312 PMID: 39544692
- 8. Petrova YD et al.. 2019. Identification of novel small-molecule inhibitors of α-methylacyl-CoA racemase (AMACR; P504S) and structure-activity relationships.. Bioorg Chem 92:103264 PMID: 31536955
